GlassScriptPhysician profile
Eugene C Taylor
NPI 1861557035
$2,640.58
in general payments reported to CMS, 2019-2025
30 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $222 · 2021: $341 · 2022: $715 · 2023: $544 · 2024: $456 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.66 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $686.49 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $315.57 | 2021-2024 | |
| Abbott Laboratories | $215.11 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $169.89 | 2023-2024 | Veozah |
| Lilly USA, LLC | $157.35 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $155.56 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $106.01 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.77 | 2021-2023 | Jardiance |
| Amarin Pharma, INC. | $81.30 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $68.61 | 2020-2023 | Gardasil 9, Vaxneuvance |
| Optinose US, INC. | $64.78 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $60.26 | 2019-2022 | |
| Daiichi Sankyo INC. | $59.65 | 2022-2023 | Injectafer |
| Sanofi Pasteur INC. | $44.12 | 2023-2024 | |
| Glaxosmithkline, LLC. | $42.02 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $41.16 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $34.12 | 2025 | Repatha, Otezla |
| Eisai INC. | $27.13 | 2021 | |
| Abbvie INC. | $22.87 | 2024 | |
| Alnylam Pharmaceuticals INC. | $20.26 | 2024 | Givlaari |
| Alexion Pharmaceuticals, INC. | $19.87 | 2022 | |
| Horizon Therapeutics Plc | $18.77 | 2019 | |
| Watermark Medical, INC. | $18.54 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.34 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.15 | 2021 | |
| Esperion Therapeutics, INC. | $16.96 | 2024 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.85 | 2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $14.56 | 2022 | |
| Nevro Corp. | $13.20 | 2024 | Senza |
| Janssen Pharmaceuticals, INC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.